<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751114</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_C_02761</org_study_id>
    <secondary_id>2008-000516-32</secondary_id>
    <nct_id>NCT00751114</nct_id>
  </id_info>
  <brief_title>Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients</brief_title>
  <acronym>EASIE</acronym>
  <official_title>Superiority Study of Insulin Glargine Over Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Treated With Metformin and Not Adequately Controlled</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective was to demonstrate the superiority of insulin glargine over sitagliptin
      in reducing Glycosylated Hemoglobin A1c (HbA1c) from baseline to the end of the treatment
      period.

      Secondary objective was to assess the effect of insulin glargine in comparison with
      sitagliptin on:

        -  HbA1c level

        -  Fasting Plasma Glucose (FPG)

        -  7-point plasma glucose (PG) profiles

        -  Percentage of patients with HbA1c &lt;7% and &lt;6.5%

      Safety objectives consisted of:

        -  Hypoglycemia occurrence

        -  Body weight

        -  Overall safety
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c: Change From Baseline to Study Endpoint</measure>
    <time_frame>baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14</time_frame>
    <description>Change in HbA1c from baseline to study endpoint defined as the last available HbA1c value measured during the 24-week treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c &lt; 7% at Study Endpoint</measure>
    <time_frame>study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c &lt; 6.5% at Study Endpoint</measure>
    <time_frame>study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint</measure>
    <time_frame>baseline (week 0), study endpoint: visit 14 (week 24) or visit 12 (week 16) or visit 11 (week 12) or visit 8 (week 6) depending on last available value</time_frame>
    <description>SMFPG mean = mean of the fasting plasma glucose values recorded on the 6 consecutive days before the visit (at least 3 values needed).
Study endpoint was defined as the last available SMFPG mean value collected on-treatment.
Change= study endpoint - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint</measure>
    <time_frame>baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14</time_frame>
    <description>7-point plasma glucose recorded before and after breakfast, before and after lunch, before and after dinner and at bedtime.
Change = study endpoint - baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Dose in the Insulin Glargine Group</measure>
    <time_frame>visit 4 (week 2), visit 8 (week 6), visit 11 (week 12), visit 12 (week 16), visit 14 (week 24), first dose received defined as first available value, study endpoint defined as last available value</time_frame>
    <description>Daily dose at the face-to-face visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile: Change From Baseline to Study Endpoint</measure>
    <time_frame>baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight From Baseline to Study Endpoint</measure>
    <time_frame>baseline (week 0), study endpoint: visit 14 (week 24) or visit 12 (week 16) or visit 11 (week 12) or visit 8 (week 6) depending on last available value</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One Episode of Symptomatic Hypoglycemia</measure>
    <time_frame>During the treatment phase (24 weeks) plus 7 days after last dose</time_frame>
    <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia confirmed or not by a plasma glucose measurement &lt;= 70mg/dL [3.9 mmol/L]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One Episode of Severe Symptomatic Hypoglycemia</measure>
    <time_frame>During the treatment phase (24 weeks) plus 7 days after last dose</time_frame>
    <description>Severe symptomatic hypoglycemia was defined as an event with clinical symptoms which required assistance of another person and with either a Plasma Glucose level &lt; 36 mg/dL (2 mmol/L) or with a prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">515</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose of 100 mg once a day administered with or without food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).</description>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <other_name>Lantus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Oral administration. 100 mg film-coated tablets.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Patients continued with metformin as usual oral anti-diabetic treatment.</description>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With type 2 diabetes diagnosed for at least 6 months,

          -  Not previously treated with insulin,

          -  On metformin for at least 3 months and a stable minimal dose of 1 g/day for at least 2
             months

          -  HbA1c ≥ 7 and &lt; 11 %,

          -  Body Mass Index (BMI) between 25 and 45 kg/m² inclusively,

          -  Ability and willingness to perform plasma glucose (PG) monitoring using the
             Sponsor-provided PG meter and to complete the patient diary,

          -  Signed informed consent obtained prior any study procedures,

          -  Willingness and ability to comply with the study protocol.

        Exclusion Criteria:

          -  Treatment with oral antidiabetic drugs other than metformin within the last 3 months,

          -  Previous treatment with the combination of metformin + sulfonylurea for more than 1
             year,

          -  Previous treatment with Glucagon Like Peptide-1 (GLP-1) agonists or DiPeptidyl
             Peptidase (DPP) IV inhibitors,

          -  FPG (assessed by central laboratory measurement) ≥ 280 mg/dL (15.4 mmol/L),

          -  Diabetes other than type 2 diabetes (e.g. secondary to pancreatic disorders, drug or
             chemical agents intake...),

          -  Pregnant or lactating women (women of childbearing potential must have a negative
             pregnancy test at study entry and a medically approved contraception method),

          -  In-patient care,

          -  Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy
             occurrence in the 6 months prior to visit 1, or any other unstable (rapidly
             progressing) retinopathy that may require photocoagulation or surgical treatment
             during the study (an optic fundus examination should have been performed within the 2
             years prior to study entry),

          -  Impaired renal function: serum creatinine ≥ 1.5 mg/dL (≥ 133µmol/L) or ≥ 1.4 mg/dL (≥
             124 µmol/L) in men and women, respectively,

          -  History of sensitivity to the study drugs or to drugs with a similar chemical
             structure,

          -  Impaired hepatic function: alanine aminotransferase (ALT), aspartate aminotransferase
             (AST) &gt; 3 x upper limit of normal range,

          -  Treatment with systemic corticosteroids within the 3 months prior to study entry or
             likelihood of requiring treatment during the study that are not permitted during the
             study (exception: in case of chronic adrenal insufficiency, systemic glucosteroids are
             accepted only if the disease is stable and the treatment dose stable for at least 3
             months before study entry),

          -  Alcohol or drug abuse within the last year,

          -  Night shift worker,

          -  Presence of any condition (medical, psychological, social or geographical), current or
             anticipated that the investigator feels would compromise the patient's safety or limit
             the patient successful participation in the study,

          -  Treatment with weight loss medications (e.g. sibutramine, orlistat, rimonabant) within
             the last 3 months,

          -  Participation in another clinical trial within the month prior to visit 1,

          -  History of pancreatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kallithea</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Col. Coyoacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Egypt</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Romania</country>
  </removed_countries>
  <results_reference>
    <citation>Aschner P, Chan J, Owens DR, Picard S, Wang E, Dain MP, Pilorget V, Echtay A, Fonseca V; EASIE investigators. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012 Jun 16;379(9833):2262-9. doi: 10.1016/S0140-6736(12)60439-5. Epub 2012 Jun 9.</citation>
    <PMID>22683131</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2008</study_first_submitted>
  <study_first_submitted_qc>September 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2008</study_first_posted>
  <results_first_submitted>July 6, 2012</results_first_submitted>
  <results_first_submitted_qc>August 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2012</results_first_posted>
  <last_update_submitted>September 3, 2012</last_update_submitted>
  <last_update_submitted_qc>September 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>EASIE was a multicenter, international, randomized, open‐label trial conducted from November 12, 2008 to July 28, 2011.</recruitment_details>
      <pre_assignment_details>A total of 732 patients were screened in 96 centers in 17 countries. The study included an initial 2‐week screening period. A total of 217 patients were screen failures. The main reason for screen failure was Glycosylated Hemoglobin A1c (HbA1c) inclusion criterion not met (146 patients).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Glargine</title>
          <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the Fasting Plasma Glucose (FPG) target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin</title>
          <description>Dose of 100 mg once a day administered with or without food</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="250">randomized</participants>
                <participants group_id="P2" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED = Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="237">safety population: randomized patients who received at least one dose of investigational product</participants>
                <participants group_id="P2" count="264"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>mITT Population</title>
              <participants_list>
                <participants group_id="P1" count="227">modified Intent-To-Treat population: treated patients with at least 1 on-treatment efficacy measure</participants>
                <participants group_id="P2" count="253"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="233"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Out of country for 2 months</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Move to another city</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin Glargine</title>
          <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin</title>
          <description>Dose of 100 mg once a day administered with or without food</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="227"/>
            <count group_id="B2" value="253"/>
            <count group_id="B3" value="480"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>mITT population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="8.9"/>
                    <measurement group_id="B2" value="53.3" spread="8.7"/>
                    <measurement group_id="B3" value="53.6" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>mITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <description>mITT population</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.4" spread="18.2"/>
                    <measurement group_id="B2" value="84.2" spread="18.3"/>
                    <measurement group_id="B3" value="83.8" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>mITT population</description>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.05" spread="4.93"/>
                    <measurement group_id="B2" value="31.13" spread="4.95"/>
                    <measurement group_id="B3" value="31.09" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>mITT population</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129.8" spread="13.3"/>
                    <measurement group_id="B2" value="131.7" spread="15.1"/>
                    <measurement group_id="B3" value="130.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>mITT population</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.5" spread="8.7"/>
                    <measurement group_id="B2" value="80.0" spread="8.3"/>
                    <measurement group_id="B3" value="79.7" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Rate</title>
          <description>mITT population</description>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.6" spread="8.7"/>
                    <measurement group_id="B2" value="76.3" spread="9.3"/>
                    <measurement group_id="B3" value="76.0" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <description>mITT population</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" lower_limit="1.9" upper_limit="8.2"/>
                    <measurement group_id="B2" value="4.8" lower_limit="1.9" upper_limit="8.2"/>
                    <measurement group_id="B3" value="4.5" lower_limit="1.9" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>At least one diabetic late complication</title>
          <description>mITT population
Diabetic late complications: myocardial infarction, angina pectoris, coronary artery disease, heart failure, stroke, transient ischemic attack, peripheral vascular disease, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin A1c (HbA1c)</title>
          <description>mITT population</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="1.0"/>
                    <measurement group_id="B2" value="8.5" spread="1.1"/>
                    <measurement group_id="B3" value="8.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <description>mITT population but due to missing values, N=225 for Insulin Glargine and N=248 for Sitagliptin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163.6" spread="42.0"/>
                    <measurement group_id="B2" value="171.1" spread="41.5"/>
                    <measurement group_id="B3" value="167.5" spread="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Self-monitored Fasting Plasma Glucose</title>
          <description>mITT population but due to missing values, N=216 for Insulin Glargine and N=244 for Sitagliptin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163.9" spread="37.6"/>
                    <measurement group_id="B2" value="166.7" spread="38.2"/>
                    <measurement group_id="B3" value="165.4" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <description>mITT population but due to missing values, N=225 for Insulin Glargine and N=248 for Sitagliptin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185.9" spread="41.4"/>
                    <measurement group_id="B2" value="187.1" spread="39.0"/>
                    <measurement group_id="B3" value="186.5" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-Density Lipoprotein (HDL) Cholesterol</title>
          <description>mITT population but due to missing values, N=225 for Insulin Glargine and N=248 for Sitagliptin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="14.6"/>
                    <measurement group_id="B2" value="45.0" spread="11.2"/>
                    <measurement group_id="B3" value="45.6" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-Density Lipoprotein (LDL) Cholesterol</title>
          <description>mITT population but due to missing values, N=225 for Insulin Glargine and N=248 for Sitagliptin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112.7" spread="36.2"/>
                    <measurement group_id="B2" value="114.2" spread="33.2"/>
                    <measurement group_id="B3" value="113.5" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <description>mITT population but due to missing values, N=225 for Insulin Glargine and N=248 for Sitagliptin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190.9" spread="142.0"/>
                    <measurement group_id="B2" value="185.7" spread="114.6"/>
                    <measurement group_id="B3" value="188.2" spread="128.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c: Change From Baseline to Study Endpoint</title>
        <description>Change in HbA1c from baseline to study endpoint defined as the last available HbA1c value measured during the 24-week treatment period.</description>
        <time_frame>baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had both baseline and endpoint measurements.
The Last Observation Carried Forward method was used for imputing missing data for the end of treatment value.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Dose of 100 mg once a day administered with or without food</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c: Change From Baseline to Study Endpoint</title>
          <description>Change in HbA1c from baseline to study endpoint defined as the last available HbA1c value measured during the 24-week treatment period.</description>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had both baseline and endpoint measurements.
The Last Observation Carried Forward method was used for imputing missing data for the end of treatment value.</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="0.06"/>
                    <measurement group_id="O2" value="-1.13" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: no difference between insulin glargine mean HbA1c change and sitagliptin mean HbA1c change
H1: difference between insulin glargine mean HbA1c change and sitagliptin mean HbA1c change
Assuming:
Estimated standard deviation of the change in HbA1c of 1.3%
Expected mean difference to be detected of 0.4%
Alpha risk of 5% (two-sided)
Power of 90%
Equal sample size in each treatment group (1:1 randomization)
A total number of 446 evaluable patients (223 in each group) was required</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>An analysis of covariance (ANCOVA) was performed, with the HbA1c change from baseline to last on-treatment measurement as dependent variable, treatment as fixed effect and the corresponding baseline HbA1c value as covariate</p_value_desc>
            <method>ANCOVA</method>
            <param_type>adjusted mean difference</param_type>
            <param_value>-0.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
            <estimate_desc>Difference (Insulin glargine - Sitagliptin)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c &lt; 7% at Study Endpoint</title>
        <time_frame>study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had endpoint measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Dose of 100 mg once a day administered with or without food</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c &lt; 7% at Study Endpoint</title>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had endpoint measurements.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9"/>
                    <measurement group_id="O2" value="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c &lt; 6.5% at Study Endpoint</title>
        <time_frame>study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had endpoint measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Dose of 100 mg once a day administered with or without food</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c &lt; 6.5% at Study Endpoint</title>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had endpoint measurements.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2"/>
                    <measurement group_id="O2" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint</title>
        <description>SMFPG mean = mean of the fasting plasma glucose values recorded on the 6 consecutive days before the visit (at least 3 values needed).
Study endpoint was defined as the last available SMFPG mean value collected on-treatment.
Change= study endpoint - baseline</description>
        <time_frame>baseline (week 0), study endpoint: visit 14 (week 24) or visit 12 (week 16) or visit 11 (week 12) or visit 8 (week 6) depending on last available value</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had both baseline and endpoint measurements.
Adjusted means were estimated from ANCOVA model using baseline value as covariate.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Dose of 100 mg once a day administered with or without food</description>
          </group>
        </group_list>
        <measure>
          <title>Self-monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint</title>
          <description>SMFPG mean = mean of the fasting plasma glucose values recorded on the 6 consecutive days before the visit (at least 3 values needed).
Study endpoint was defined as the last available SMFPG mean value collected on-treatment.
Change= study endpoint - baseline</description>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had both baseline and endpoint measurements.
Adjusted means were estimated from ANCOVA model using baseline value as covariate.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.52" spread="1.85"/>
                    <measurement group_id="O2" value="-19.35" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint</title>
        <description>7-point plasma glucose recorded before and after breakfast, before and after lunch, before and after dinner and at bedtime.
Change = study endpoint - baseline.</description>
        <time_frame>baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had valid 7-point plasma glucose profiles (4 points needed for a valid profile) both at baseline and endpoint.
Depending on the time point, few values were missing.
Adjusted means were estimated from ANCOVA model using baseline value as covariate.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Dose of 100 mg once a day administered with or without food</description>
          </group>
        </group_list>
        <measure>
          <title>7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint</title>
          <description>7-point plasma glucose recorded before and after breakfast, before and after lunch, before and after dinner and at bedtime.
Change = study endpoint - baseline.</description>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had valid 7-point plasma glucose profiles (4 points needed for a valid profile) both at baseline and endpoint.
Depending on the time point, few values were missing.
Adjusted means were estimated from ANCOVA model using baseline value as covariate.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before breakfast (N ig = 203 &amp; N s = 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.90" spread="2.02"/>
                    <measurement group_id="O2" value="-20.39" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After breakfast (N ig = 202 &amp; N s = 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.25" spread="3.03"/>
                    <measurement group_id="O2" value="-36.41" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before lunch (N ig = 201 &amp; N s = 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.00" spread="2.33"/>
                    <measurement group_id="O2" value="-19.82" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After lunch (N ig = 202 &amp; N s = 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.54" spread="2.82"/>
                    <measurement group_id="O2" value="-26.10" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before dinner (N ig = 199 &amp; N s = 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.68" spread="2.61"/>
                    <measurement group_id="O2" value="-25.07" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After dinner (N ig = 196 &amp; N s = 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.88" spread="2.69"/>
                    <measurement group_id="O2" value="-33.78" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At bedtime (N ig = 177 &amp; N s = 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.58" spread="3.15"/>
                    <measurement group_id="O2" value="-31.16" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Dose in the Insulin Glargine Group</title>
        <description>Daily dose at the face-to-face visits.</description>
        <time_frame>visit 4 (week 2), visit 8 (week 6), visit 11 (week 12), visit 12 (week 16), visit 14 (week 24), first dose received defined as first available value, study endpoint defined as last available value</time_frame>
        <population>The population analyzed for this outcome was the safety population defined as randomized patients who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Dose in the Insulin Glargine Group</title>
          <description>Daily dose at the face-to-face visits.</description>
          <population>The population analyzed for this outcome was the safety population defined as randomized patients who received at least one dose of investigational product.</population>
          <units>unit per kg body weight</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First dose received N=236</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 2) N=230</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (week 6) N=222</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (week 12) N=219</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 (week 16) N=214</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (week 24) N=220</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study endpoint N=237</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Profile: Change From Baseline to Study Endpoint</title>
        <time_frame>baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had both baseline and endpoint measurements.
Adjusted means were estimated from ANCOVA model using baseline value as covariate.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Dose of 100 mg once a day administered with or without food</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Profile: Change From Baseline to Study Endpoint</title>
          <population>The population analyzed for this outcome measure consisted of the subset of mITT patients who had both baseline and endpoint measurements.
Adjusted means were estimated from ANCOVA model using baseline value as covariate.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.94" spread="2.06"/>
                    <measurement group_id="O2" value="-1.54" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.68" spread="1.71"/>
                    <measurement group_id="O2" value="-0.19" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.54"/>
                    <measurement group_id="O2" value="0.57" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.07" spread="8.14"/>
                    <measurement group_id="O2" value="0.31" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight From Baseline to Study Endpoint</title>
        <time_frame>baseline (week 0), study endpoint: visit 14 (week 24) or visit 12 (week 16) or visit 11 (week 12) or visit 8 (week 6) depending on last available value</time_frame>
        <population>The population analyzed for this outcome measure consisted of the subset of the safety population (treated patients) who had both baseline and endpoint measurements.
Adjusted means were estimated from ANCOVA model using baseline value as covariate.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Dose of 100 mg once a day administered with or without food</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight From Baseline to Study Endpoint</title>
          <population>The population analyzed for this outcome measure consisted of the subset of the safety population (treated patients) who had both baseline and endpoint measurements.
Adjusted means were estimated from ANCOVA model using baseline value as covariate.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.22"/>
                    <measurement group_id="O2" value="-1.08" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One Episode of Symptomatic Hypoglycemia</title>
        <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia confirmed or not by a plasma glucose measurement &lt;= 70mg/dL [3.9 mmol/L]</description>
        <time_frame>During the treatment phase (24 weeks) plus 7 days after last dose</time_frame>
        <population>The population analyzed for this outcome measure was the safety population (treated patients)</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Dose of 100 mg once a day administered with or without food</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One Episode of Symptomatic Hypoglycemia</title>
          <description>Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia confirmed or not by a plasma glucose measurement &lt;= 70mg/dL [3.9 mmol/L]</description>
          <population>The population analyzed for this outcome measure was the safety population (treated patients)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One Episode of Severe Symptomatic Hypoglycemia</title>
        <description>Severe symptomatic hypoglycemia was defined as an event with clinical symptoms which required assistance of another person and with either a Plasma Glucose level &lt; 36 mg/dL (2 mmol/L) or with a prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration</description>
        <time_frame>During the treatment phase (24 weeks) plus 7 days after last dose</time_frame>
        <population>The population analyzed for this outcome measure was the safety population (treated patients)</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine</title>
            <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Dose of 100 mg once a day administered with or without food</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One Episode of Severe Symptomatic Hypoglycemia</title>
          <description>Severe symptomatic hypoglycemia was defined as an event with clinical symptoms which required assistance of another person and with either a Plasma Glucose level &lt; 36 mg/dL (2 mmol/L) or with a prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration</description>
          <population>The population analyzed for this outcome measure was the safety population (treated patients)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed throughout the study (24 weeks). Mean duration of exposure to insulin glargine was 157.7 ± 40.9 days (ranging from 1 to 211 days) and 160.8 ± 33.7 days to sitagliptin (ranging from 14 to 262 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Insulin Glargine</title>
          <description>Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL&lt;FPG≤100mg/dL (3.9mmol/L&lt;FPG≤5.5mmol/L)</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin</title>
          <description>Dose of 100 mg once a day administered with or without food</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 45 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

